CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Dr Reddy's Laboratories Ltd

1:14-cv-00157

Overview

Case Number 1:14-cv-00157
Filing Date 2014-02-05
Status Terminated
Termination Date 2015-06-22
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Dr. Reddy's Laboratories Inc. Operating Company

Represented By

1 Attorneys Listed

Neal C. Belgam

Smith, Katzenstein, & Jenkins LLP

Tel: +1 (302) 652-8400

1000 West Street, Suite 1501, Wilmington, DE 19801

Dr Reddy's Laboratories Ltd Operating Company

Represented By

4 Attorneys Listed

Constance S. Huttner

Email: chuttner@windelsmarx.com

Alan H. Pollack

Email: apollack@windelsmarx.com

Ajay Kayal

Email: akayal@buddlarner.com

Neal C. Belgam

Smith, Katzenstein, & Jenkins LLP

Tel: +1 (302) 652-8400

1000 West Street, Suite 1501, Wilmington, DE 19801

Plaintiff

Novartis AG Operating Company

Represented By

2 Attorneys Listed

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

3 Attorneys Listed

David K. Barr

Email: david.barr@arnoldporter.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Michael P. Kelly

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 984-6399

Renaissance Centre, 405 N. King Street, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 6 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (6): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6894051
Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Filed: 1998-07-16
Issued: 2005-05-17
Expired (Term Ended) +311d PTA
Expires: 2019-05-23

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+311 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

16

Dispositive

0

Granted

0

Denied

0

Pending / Review

8

Motions by Category

Procedural / Extension Motion 16

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re (24 in 1:14-cv-00157-LPS, 15 in 1:14-cv-01076-LPS, 19 in 1:14-cv-00387-LPS, 13 in 1:14-cv-01283-LPS) STIPULATION TO EXTEND TIME regarding the Dea...
Entry #β€” • 2015-05-06
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME regarding the Deadline for the Parties to Submit a Proposed Scheduling Order to Wednesday, July 8, 2015 (from Friday, May 8, 2015) - ...
Entry #24 • 2015-05-05 Document →
Procedural / Extension Motion Pending
SO ORDERED, re (18 in 1:14-cv-00387-LPS, 23 in 1:14-cv-00157-LPS, 14 in 1:14-cv-01076-LPS, 12 in 1:14-cv-01283-LPS) STIPULATION TO EXTEND TIME for the Parties t...
Entry #β€” • 2015-02-27
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for the Parties to Submit a Proposed Scheduling Order to Friday, May 8, 2015 (from Monday, March 9, 2015 in C.A. No. 14-157 and Monda...
Entry #23 • 2015-02-26 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 22 STIPULATION TO EXTEND TIME for the Parties to Submit a Proposed Schedule to Monday, March 9, 2015 (from February 9, 2015) filed by Novartis AG...
Entry #β€” • 2015-02-13
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for the Parties to Submit a Proposed Schedule to Monday, March 9, 2015 (from February 9, 2015) - filed by Novartis AG, Novartis Pharm...
Entry #22 • 2015-02-06 Document →

Docket Entries

(46 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Dr Reddy's Laboratories Ltd, Dr. Reddy's Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1455789.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(els) (Entered: 02/06/2014)

Entry #1 • 2014-02-05
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (els) (Entered: 02/06/2014)

Entry #2 • 2014-02-05
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/24/13. Date of Expiration of Patent: 5/23/19.Thirty Month Stay Deadline: 6/24/2016. (els) (Entered: 02/06/2014)

Entry #3 • 2014-02-05
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,894,051;. (els) (Entered: 02/06/2014)

Entry #4 • 2014-02-05
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (els) (Entered: 02/06/2014)

Entry #5 • 2014-02-05
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc